Matrix Therapy Company
in Regenerative Medicine
Bringing
Matrix Therapy
from research
to patients
OTR3, the leading biotechnology company in Matrix Therapy, is fully committed to the development of new therapies based on the revolutionary RGTA® technology.
The RGTA®
Technology
ReGeneraTing Agents (RGTA®) help restore the natural micro-environment around cells, promoting tissue regeneration.
Research & Development
OTR3® is a biotechnology company with a strong lead in Research and Development, which excellence has been recognized by the European Commission (SME H2020 Instrument) and the French National Research Agency (ANR).
Our products
CACIPLIQ20® is the first therapeutic product based on the innovative RGTA® technology.
CACIPLIQ20 ®
This CE marked medical device promotes natural skin regeneration. CACIPLIQ20® is intended to improve the healing of chronic cutaneous ulcers.
